IL245880B - Antibodies against the IgM-related b-cell receptor system and their uses - Google Patents
Antibodies against the IgM-related b-cell receptor system and their usesInfo
- Publication number
- IL245880B IL245880B IL245880A IL24588016A IL245880B IL 245880 B IL245880 B IL 245880B IL 245880 A IL245880 A IL 245880A IL 24588016 A IL24588016 A IL 24588016A IL 245880 B IL245880 B IL 245880B
- Authority
- IL
- Israel
- Prior art keywords
- cell receptor
- receptor complex
- membrane bound
- antibodies targeting
- complex membrane
- Prior art date
Links
- 108091008875 B cell receptors Proteins 0.000 title 1
- 239000012528 membrane Substances 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361911186P | 2013-12-03 | 2013-12-03 | |
| PCT/US2014/067957 WO2015084736A2 (en) | 2013-12-03 | 2014-12-01 | Antibodies targeting b-cell receptor complex membrane bound igm and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL245880A0 IL245880A0 (en) | 2016-07-31 |
| IL245880B true IL245880B (en) | 2020-09-30 |
Family
ID=53274268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL245880A IL245880B (en) | 2013-12-03 | 2016-05-26 | Antibodies against the IgM-related b-cell receptor system and their uses |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9926381B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3077010B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6535668B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN106456809B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2014357450B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2931779C (cg-RX-API-DMAC7.html) |
| IL (1) | IL245880B (cg-RX-API-DMAC7.html) |
| SG (1) | SG10201709164UA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015084736A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3123352A1 (en) * | 2018-12-20 | 2020-06-25 | Ava Lifescience Gmbh | Method for selecting biological binding molecules |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6633090A (en) | 1989-09-15 | 1991-04-18 | Akzo N.V. | Compartmentalized container for a plurality of small articles |
| ATE148348T1 (de) * | 1989-09-15 | 1997-02-15 | Tanox Biosystems Inc | Behandlung von einer autoimmun-krankheit |
| US8137670B2 (en) * | 2005-09-29 | 2012-03-20 | Medimmune, Llc | Method of identifying membrane IgE specific antibodies and use thereof for targeting IgE producing precursor cells |
| JP2009536217A (ja) * | 2006-05-03 | 2009-10-08 | ガスリー ファンデーション フォー エデュケーション アンド リサーチ | Ｂ細胞障害の治療における免疫グロブリン結合細胞表面決定基 |
| SG174053A1 (en) * | 2006-09-01 | 2011-09-29 | Therapeutic Human Polyclonals Inc | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
| DK3284825T3 (da) * | 2006-11-02 | 2021-05-25 | Biomolecular Holdings Llc | Fremgangsmåder til at fremstille hybride polypeptider med bevægelige dele |
| EP1972640A1 (en) * | 2007-03-23 | 2008-09-24 | Biomay AG | Apoptosis inducing antibodies |
| WO2011064758A2 (en) * | 2009-11-30 | 2011-06-03 | Pfizer Limited | Fusion protein |
| US9540657B2 (en) * | 2012-05-25 | 2017-01-10 | California Institute Of Technology | Expression of secreted and cell-surface polypeptides |
-
2014
- 2014-12-01 EP EP14867840.2A patent/EP3077010B1/en active Active
- 2014-12-01 WO PCT/US2014/067957 patent/WO2015084736A2/en not_active Ceased
- 2014-12-01 AU AU2014357450A patent/AU2014357450B2/en active Active
- 2014-12-01 SG SG10201709164UA patent/SG10201709164UA/en unknown
- 2014-12-01 CN CN201480074580.7A patent/CN106456809B/zh active Active
- 2014-12-01 JP JP2016533109A patent/JP6535668B2/ja active Active
- 2014-12-01 US US15/101,658 patent/US9926381B2/en active Active
- 2014-12-01 CA CA2931779A patent/CA2931779C/en active Active
-
2016
- 2016-05-26 IL IL245880A patent/IL245880B/en active IP Right Grant
-
2018
- 2018-02-13 US US15/895,386 patent/US10227419B2/en active Active
-
2019
- 2019-09-11 AU AU2019229346A patent/AU2019229346A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL245880A0 (en) | 2016-07-31 |
| AU2014357450B2 (en) | 2019-10-03 |
| EP3077010A4 (en) | 2017-08-02 |
| JP2016540504A (ja) | 2016-12-28 |
| AU2019229346A1 (en) | 2019-10-03 |
| WO2015084736A3 (en) | 2016-01-21 |
| WO2015084736A2 (en) | 2015-06-11 |
| US10227419B2 (en) | 2019-03-12 |
| US9926381B2 (en) | 2018-03-27 |
| SG10201709164UA (en) | 2017-12-28 |
| EP3077010A2 (en) | 2016-10-12 |
| AU2014357450A1 (en) | 2016-07-14 |
| JP6535668B2 (ja) | 2019-06-26 |
| US20180186895A1 (en) | 2018-07-05 |
| CN106456809A (zh) | 2017-02-22 |
| WO2015084736A4 (en) | 2016-02-25 |
| US20160304625A1 (en) | 2016-10-20 |
| CA2931779A1 (en) | 2015-06-11 |
| EP3077010B1 (en) | 2020-04-01 |
| CA2931779C (en) | 2023-04-25 |
| CN106456809B (zh) | 2020-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287824A (en) | Oncostatin m receptor antigen-binding proteins | |
| IL237576B (en) | Multichain chimeric antigen receptor and its uses | |
| IL244784A0 (en) | chimeric antigen receptor | |
| EP3083964A4 (en) | Human mesothelin chimeric antigen receptors and uses thereof | |
| ZA201500457B (en) | Anti-kit antibodies and uses thereof | |
| SG11201508805UA (en) | Cd19 specific chimeric antigen receptor and uses thereof | |
| IL239500A0 (en) | Chimeric antigen receptors | |
| EP3087101A4 (en) | Regulatable chimeric antigen receptor | |
| IL244135A0 (en) | Antibodies against fc gamma iib receptors and uses thereof | |
| LT2814843T (lt) | ŽMOGAUS MONOKLONINIAI ANTIKŪNAI, NEUTRALIZUOJANTYS IL-1ß | |
| PT3016977T (pt) | Anticorpos humanos anti-il-32 | |
| ZA201507251B (en) | Antibodies targeting m-csf | |
| SG11201602760YA (en) | Monoclonal olfml-3 antibodies and uses thereof | |
| IL245880A0 (en) | Antibodies against the IgM-related b-cell receptor system and their uses | |
| IL238629A0 (en) | Antibodies against prokinectin receptor and their uses | |
| EP3071599A4 (en) | Hyper-glycosylated antibodies with selective fc receptor binding | |
| EP3066122A4 (en) | Pre-haptoglobin-2 monoclonal antibodies and uses thereof | |
| ZA201508068B (en) | Cd19 specific chimeric antigen receptor and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |